{"ticker": {"uuid": "01375501-71ca-44d9-ab28-f75ee33bd267", "symbol": "ANIX", "name": "Anixa Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "CEO Amit Kumar Increases Stake in Anixa Biosciences Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQZ2E3QUtZbl9Lc2RvSlZ0SVQ1Q3NMckp4WkJHZ2ZuTVlkSU5IQ21KRkNqNjJWR1d6VG8xZDBGdW9hNWpxdW1RamtYamJPNE9mOVhQOWZaOTBpcVVNMTZwUFBOVDBraGJuY3J6MjNxNURSN3ZTU216ZzdUMG5PQ294TlJyTWoybWVmT0tmdGJlc29TeVZNZTFfRnR3?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-22T00:30:35+00:00", "published_display": "22 Jul 2026 00:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) CEO buys 5,000 common shares", "summary": "Anixa Biosciences Inc.'s CEO and director, Amit Kumar, purchased 5,000 shares of common stock at $3.46 per share on July 20, 2026. This transaction was an open-market or private purchase, increasing his direct holdings to 640,812 shares. The purchase was not made under a Rule 10b", "url": "https://www.stocktitan.net/sec-filings/ANIX/form-4-anixa-biosciences-inc-insider-trading-activity-ce1b9ddfcf24.html", "source_name": "Stock Titan", "published_at": "2026-07-21T14:41:38", "published_display": "21 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Titterton Lewis H Jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX)", "summary": "Titterton Lewis H Jr, a Director at Anixa Biosciences Inc (ANIX), recently purchased 12,000 shares of the company, increasing his total holdings to 986,967 shares. This purchase is part of a trend of insider buying at ANIX, with 8 insider buys and no sells in the past year. Share", "url": "https://www.gurufocus.com/news/8967959/insider-buying-titterton-lewis-h-jr-acquires-additional-shares-of-anixa-biosciences-inc-anix", "source_name": "GuruFocus", "published_at": "2026-07-21T00:40:43", "published_display": "21 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) director purchases 12,000 shares of common stock", "summary": "Anixa Biosciences director Lewis H. Titterton Jr. purchased 12,000 shares of common stock on July 20, 2026, at $3.47 per share. This transaction increases his direct holdings to 986,967 shares and was classified as an open market or private purchase. The Form 4 filing indicates a", "url": "https://www.stocktitan.net/sec-filings/ANIX/form-4-anixa-biosciences-inc-insider-trading-activity-b1f0031c3220.html", "source_name": "Stock Titan", "published_at": "2026-07-20T22:40:43", "published_display": "20 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Friday's Pre-Market Session", "summary": "This article lists 12 health care stocks experiencing significant movement in Friday's pre-market trading session. It provides details on both gainers like Anixa Biosciences and Barinthus Biotherapeutics, and losers such as Regenxbio and Liminatus Pharma, including their stock pe", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60520138/12-health-care-stocks-moving-friday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-17T12:11:31", "published_display": "17 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences director buys $9,174 in common stock", "summary": "Anixa Biosciences director Lewis H. Titterton Jr. purchased 2,797 shares of common stock for $9,174 on July 15, 2026, increasing his direct holdings to 974,967 shares. Despite the stock's recent gain, InvestingPro suggests the company may be overvalued. Anixa Biosciences is also ", "url": "https://www.investing.com/news/insider-trading-news/anixa-biosciences-director-buys-9174-in-common-stock-93CH-4795886", "source_name": "Investing.com", "published_at": "2026-07-17T02:11:47", "published_display": "17 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi", "summary": "On July 15, 2026, Anixa Biosciences Inc Director Titterton Lewis H Jr purchased 2,797 shares, increasing his total holdings to 974,967 shares. This transaction reflects positive insider sentiment, as he has acquired 15,633 shares over the past year without any sales. The company ", "url": "https://www.gurufocus.com/news/8962658/insider-buying-titterton-lewis-h-jr-increases-stake-in-anixa-biosciences-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-16T15:09:34", "published_display": "16 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences director buys $9,174 in common stock By Investing.com", "summary": "A director at Anixa Biosciences Inc. (NASDAQ: ANIX), Lewis H. Titterton Jr., purchased 2,797 shares of common stock for $9,174. The company has recently made strides in its clinical trials and intellectual property, including a Phase 1 clinical trial for a CAR-T therapy for ovari", "url": "https://ca.investing.com/news/stock-market-news/anixa-biosciences-director-buys-9174-in-common-stock-93CH-4737551", "source_name": "Investing.com Canada", "published_at": "2026-07-16T13:09:58", "published_display": "16 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Anixa Biosciences Inc For: 16 July By Investing.com", "summary": "This article reports on a Form 4 filing for Anixa Biosciences Inc. on July 16, highlighting the basic announcement without providing further details about the filing's content. It also includes various market data and other news headlines related to the financial sector.", "url": "https://ca.investing.com/news/stock-market-news/form-4-anixa-biosciences-inc-for-16-july-93CH-4737574", "source_name": "Investing.com Canada", "published_at": "2026-07-16T13:09:58", "published_display": "16 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stock", "summary": "Anixa Biosciences Inc. director Lewis H. Titterton Jr. purchased 2,797 shares of ANIX common stock on July 15, 2026, at a price of $3.28 per share. This open-market transaction increased his direct holdings to 974,967 shares. The filing was reported on a Form 4, indicating a neut", "url": "https://www.stocktitan.net/sec-filings/ANIX/form-4-anixa-biosciences-inc-insider-trading-activity-4da250bb5d09.html", "source_name": "Stock Titan", "published_at": "2026-07-16T13:09:34", "published_display": "16 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) Secures New Patent for Breast Cancer Va", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxObXRFX0JHZXE0TTAxcEZZdWh3XzZnbmk2VjR4ZUVjblFjdnhocEVKc2R5dW45dFN6TE1fLW5hVVlDd0xzWUdZbC1rcnFkaF9wRDBwbVdrQ2xpRFdzdU1RRVdXaHpnbWctdjh2dU11SVNDc3U0X1pUdm1PQlZiMjMwQkZsT2Q5Xy1BdTBLNnhtSWZSRmlPM3FUNVhNQmZMb19NQzJ4TmREakRaRmJQN1liN3BWMUs3QTJ2b0JsY0oxcUlzeXBDbTZvSEx0LU10azh1clBvUDd0OTRWUjZtSnp5dEM5blJDM1VFZUtXODdR?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T07:33:47+00:00", "published_display": "15 Jul 2026 07:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "No Approved Vaccines Prevent Breast Cancer; Anixa Expands Coverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdS03UjFHVzVHTjZXb0l5cjQ3bXByeXlSMFNiOGNvOUxOVER3WGpSWlh2dmJST2VTVmhFS25oTm1HcHZGRTd1OUpjcUJWTk5OelVPSGF6aEsyTVExekQ2UEgyUFdTV0pCNlFzV010RWFpc2NoWEd0WGlJMzNIN29jLVBwMVN5YzdqaW1mb2syNkd4NlliUU9mNzRpVjRCbUZBZDFsNTlwb1NhZy00cXBfZmRRSkp2NENQWjBfVA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T12:33:00+00:00", "published_display": "14 Jul 2026 12:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology", "summary": "Anixa Biosciences announced that IP Australia has accepted a patent for its breast cancer vaccine technology, expanding its global intellectual property portfolio. This patent, licensed from Cleveland Clinic, protects their novel approach to breast cancer treatment and prevention", "url": "https://www.prnewswire.com/news-releases/anixa-biosciences-expands-global-patent-portfolio-with-australian-patent-acceptance-for-breast-cancer-vaccine-technology-302824585.html", "source_name": "PR Newswire", "published_at": "2026-07-14T12:32:50", "published_display": "14 Jul 2026 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Recent Share Purchase", "summary": "Anixa Biosciences Inc CEO, Amit Kumar, recently purchased 5,000 shares of the company, bringing his total holdings to 635,812 shares. This transaction is part of a larger trend where Kumar has acquired 31,000 shares over the past year without any sales. The acquisition, seen as a", "url": "https://www.gurufocus.com/news/8955589/ceo-amit-kumar-increases-stake-in-anixa-biosciences-inc-with-recent-share-purchase", "source_name": "GuruFocus", "published_at": "2026-07-13T15:10:53", "published_display": "13 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Anixa Biosciences Inc For: 13 July By Investing.com", "summary": "This article reports on a Form 4 filing for Anixa Biosciences Inc. on July 13. It includes the company name and filing date, and highlights that Anixa Biosciences' stock symbol is ANIX and its price performance at the time of publication was +4.25%. The content is brief and prima", "url": "https://uk.investing.com/news/stock-market-news/form-4-anixa-biosciences-inc-for-13-july-93CH-4767943", "source_name": "Investing.com UK", "published_at": "2026-07-13T14:08:00", "published_display": "13 Jul 2026 14:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) CEO Amit Kumar buys 5,000 shares at $3.04", "summary": "Anixa Biosciences (ANIX) CEO Amit Kumar recently purchased 5,000 shares of common stock at $3.04 each, increasing his direct holdings to 635,812 shares. This open-market transaction, reported via a Form 4 SEC filing, represents a net buy of $15,200. The purchase signals confidenc", "url": "https://www.stocktitan.net/sec-filings/ANIX/form-4-anixa-biosciences-inc-insider-trading-activity-fcd882dd84cc.html", "source_name": "Stock Titan", "published_at": "2026-07-13T13:10:54", "published_display": "13 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial", "summary": "Anixa Biosciences has announced the treatment of the first patient in the fifth cohort of its ovarian cancer CAR-T clinical trial. This trial is evaluating the company's CAR T-cell therapy targeting the folate receptor alpha, a protein commonly found on ovarian cancer cells. The ", "url": "https://www.moomoo.com/news/post/72525377/anixa-biosciences-treats-first-patient-in-fifth-cohort-of-ovarian?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T06:10:00", "published_display": "07 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa\u2019s ovarian cancer CAR-T reaches highest dose, no toxicities seen", "summary": "Anixa Biosciences announced that its FSHR-targeted CAR-T/CER-T trial for recurrent ovarian cancer has advanced to its highest dose level (1x10^7 CAR-positive cells/kg) in cohort 5, with the first patient treated. The company confirmed that no dose-limiting toxicities have been ob", "url": "https://www.stocktitan.net/news/ANIX/anixa-biosciences-and-moffitt-cancer-center-advance-ovarian-cancer-t6pib2dyx1qm.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:40:55", "published_display": "06 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa doses first patient in highest cohort of ovarian trial", "summary": "Anixa Biosciences Inc. has treated the first patient in the highest dose cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer, with no dose-limiting toxicities observed to date. The therapy, liraltagene autoleucel, targets the follicle-stimu", "url": "https://www.investing.com/news/company-news/anixa-doses-first-patient-in-highest-cohort-of-ovarian-trial-93CH-4776595", "source_name": "Investing.com", "published_at": "2026-07-06T13:10:00", "published_display": "06 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10\u2076/kg dose level.", "summary": "Anixa Biosciences reported that its CAR-T cell therapy clinical trial has shown no dose-limiting toxicities up to the 3x10\u2076/kg dose level. This positive safety data is crucial for exploring higher doses and highlights the therapy's potential for patient tolerability. The company ", "url": "https://www.bitget.com/amp/news/detail/12560605492015", "source_name": "Bitget", "published_at": "2026-07-06T13:09:21", "published_display": "06 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date", "summary": "Anixa Biosciences and Moffitt Cancer Center have advanced their ovarian cancer CAR-T clinical trial to its highest dose level yet, 1x10^7 CAR-positive cells/kg, with no dose-limiting toxicities observed to date. Five patients in the study have survived over a year, with one excee", "url": "https://www.prnewswire.com/news-releases/anixa-biosciences-and-moffitt-cancer-center-advance-ovarian-cancer-car-t-clinical-trial-to-highest-dose-level-to-date-302817267.html", "source_name": "PR Newswire", "published_at": "2026-07-06T12:09:21", "published_display": "06 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIX - Anixa Biosciences Inc Revenue Breakdown", "summary": "This article provides a financial breakdown and performance overview for Anixa Biosciences Inc (ANIX). It details various financial metrics such as market capitalization, income, sales, EPS, and insider/institutional ownership. The report also includes performance indicators like", "url": "https://finviz.com/stock?t=ANIX&ta=1&p=m&ty=rv&r=y5", "source_name": "Finviz", "published_at": "2026-07-04T23:09:21", "published_display": "04 Jul 2026 23:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences secures Korean patent for breast cancer vaccine", "summary": "Anixa Biosciences has secured a Korean patent for its breast cancer vaccine technology, which is exclusively licensed from Cleveland Clinic. This patent extends intellectual property protection in South Korea through 2040, addressing the increasing incidence of breast cancer in t", "url": "https://www.biospectrumasia.com/news/26/27942/anixa-biosciences-secures-korean-patent-for-breast-cancer-vaccine.html", "source_name": "BioSpectrum Asia", "published_at": "2026-06-30T21:10:44", "published_display": "30 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Granted Korean Patent for Breast Cancer Vaccine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/anixa-biosciences-granted-korean-patent-131412869.html", "source_name": "MT Newswires", "published_at": "2026-06-29T13:14:12+00:00", "published_display": "29 Jun 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040", "summary": "Anixa Biosciences has been granted its first Korean patent for its breast cancer vaccine technology, securing exclusive protection in South Korea through 2040. This expands Anixa's global intellectual property portfolio and strengthens its ability to pursue international developm", "url": "https://www.prnewswire.com/news-releases/anixa-biosciences-granted-first-korean-patent-for-its-breast-cancer-vaccine-extending-global-protection-through-2040-302812489.html", "source_name": "PR Newswire", "published_at": "2026-06-29T13:09:50", "published_display": "29 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa gets first Korean patent for breast cancer vaccine", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQRFlxU0MxYXRvdWJvNUlwQ0xTTUk0U2phdmV6TFlBaEZkWlF5cXFUX0tmSWFkWUhJMUxWZkJFTTcxaTZiY1ZMOHBOSFJpZUFza05nU0dyTldhLUZWdmhGbHhtZ0kxUmpub0p3YTJ3Uzl6eVN6LV9JREU5M2REdldjcnlGQVByQVhheWNSS1gtNVRsa3F1bi1qSHV4RFI0ZVIzUEdYUlIySUVBYXRFSjF6WTlXaG1UT29tV09ZcXZ5TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Secures Patent for Breast Cancer Vaccine in South Korea", "summary": "Anixa has secured a composition-of-matter patent for its breast cancer vaccine in South Korea, valid until 2040, strengthening its global intellectual property. This patent addresses the rising breast cancer incidence in South Korea and supports future commercialization, followin", "url": "https://intellectia.ai/news/stock/anixa-secures-patent-for-breast-cancer-vaccine-in-south-korea", "source_name": "Intellectia AI", "published_at": "2026-06-28T20:09:50", "published_display": "28 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences, Inc. Actuals & Estimates (DUS:CY71)", "summary": "This article provides financial actuals and estimates for Anixa Biosciences, Inc. (CY71) traded on the Dusseldorf Stock Exchange. It details analyst forecasts with a price target range, historical high and low prices, upcoming earnings reports, net income for recent quarters, and", "url": "https://www.tradingview.com/symbols/DUS-CY71/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:57", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Anixa Biosciences, Inc. \u2013 NASDAQ:ANIX", "summary": "This page from TradingView displays financial information for Anixa Biosciences, Inc. (NASDAQ: ANIX), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of viewing, with no trades having occurred. The content primarily h", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:56", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium", "summary": "Anixa Biosciences announced positive data from its completed Phase 1 breast cancer vaccine trial and positive survival observations from its ongoing Phase 1 CAR-T trial for ovarian cancer. The breast cancer vaccine met all primary endpoints, demonstrating safety and immune respon", "url": "https://www.sahmcapital.com/news/content/anixa-biosciences-reports-positive-data-from-completed-breast-cancer-vaccine-phase-1-trial-and-positive-survival-observations-from-ongoing-car-t-phase-1-trial-at-new-york-academy-of-sciences-frontiers-in-cancer-immunotherapy-symposium-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-26T20:09:50", "published_display": "26 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences stock falls despite Phase 1 trial updates By Investing.com", "summary": "Anixa Biosciences Inc. (NASDAQ:ANIX) shares fell 4% despite the company presenting positive Phase 1 clinical trial data for its breast cancer vaccine and ovarian cancer CAR-T therapy. The breast cancer vaccine, developed with Cleveland Clinic, met all major primary endpoints, gen", "url": "https://m.za.investing.com/news/stock-market-news/anixa-biosciences-stock-falls-despite-phase-1-trial-updates-93CH-4346056?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-26T15:11:00", "published_display": "26 Jun 2026 15:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Anixa Biosciences, Inc. \u2013 NASDAQ:ANIX", "summary": "The article focuses on the enterprise value to EBIT forward for Anixa Biosciences, Inc. (NASDAQ: ANIX). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics in relation to its enterprise value and earnings before intere", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:11:00", "published_display": "26 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa breast cancer vaccine met endpoints; CAR-T survival data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRFRMRFlCRUl6bWpXeEJzWXI2TkRKczNhV0kwRHRvZklhU3BkVWF6UzZoMnZsVEZ0aUZ3SWdRczRQdS1KejhhS0ZVaW9rOWt3VUFLclBFVkEyZVVXakEwRTM0dU9Mc1oxd1ZLLVY5SFpqUThQTVp3SGliQTllSXZ1bldLLXJBalBtcWNsR3dEZGJOWWhueE9CR2MyeW5nS1JsLU8zVnpqRkhxaXJkWWZmSWx4RTdLbWhBWXRDT0hxSGU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) director adds 2,836 shares in open-market buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOQ05SLXBmTUtKYXN1LUExc2ZhWjVOdHRsR0xCNG1ibWtNbVdmUkVkemN5NHN1NUpwRXFKZ3QtbHpmV25WTDN1aEYwWnQ1WGVValBDWFB6X0g2bGc2UndFV1RveXRZaEI3aUwtSjF2VHlpS0VMZVFXZ21LNlBKTU5uVnk1MGstNDBvQThBWXMzMm5UVXB0bUphMURQQnY2OUx5Yzhac1ZzV0tObllpTmxSOFRXbnp5Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (NASDAQ: ANIX) CEO adds 21,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOQW1qMThnS2NKc0Y2RGdjVk5SdE1xdm9sX0RpWXpkVWpNcUFFM2xVX2ZRZWdpa3dtYXJwaFljREVxTm1yTlhNYlRMcFpTTHJTdFJiS1JSOWVULVRuZFlLaFNNSElOTGxfSmozeDc1Zmo3R1FETUhPb2hOZnVjZWlqMFltdEdJTzVoWGFHM3lfWUx6NHk0OF9zTWt2REVTLTh2Um43MUxLLTV0ZnU4ZXkxWkw0TXdiUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anixa-biosciences-announces-presentations-two-130500822.html", "source_name": "PR Newswire", "published_at": "2026-06-11T13:05:00+00:00", "published_display": "11 Jun 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Says Canadian IP Office Issues Notice of Allowance for Patent Covering Ovarian Cancer Vaccine Technology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anixa-biosciences-says-canadian-ip-134434799.html", "source_name": "MT Newswires", "published_at": "2026-06-01T13:44:34+00:00", "published_display": "01 Jun 2026 13:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anixa-biosciences-strengthens-international-patent-130000346.html", "source_name": "PR Newswire", "published_at": "2026-06-01T13:00:00+00:00", "published_display": "01 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "/C O R R E C T I O N -- Anixa Biosciences, Inc./", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anixa-biosciences-reports-updated-positive-125500267.html", "source_name": "PR Newswire", "published_at": "2026-05-11T15:48:00+00:00", "published_display": "11 May 2026 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOajNIYk1TSlBsM0tGMm54V2twWFYwR3JhaVYxTTlBUlYwd1dPUllJVmROU01TVEdTRU5pNVFMWFFrMHpDb3VNNF8xbEp0WUpCLXBWdFN6TVc4UU9QUWJSOGpIWUR5RWkxdVVXem9qdldndFN3QmtpNEJFUG1GV2Qtd3R4VkxnOWNsZ3dtelJRR0oxaW1ORHg0TkN0dll1elJKMnhQLUdJeGN1Z1hrdjNqMDV4ZVdoUjdBWUpFU1ROekQ0VUhIektVSXlDbTQ1ajlpWFBkUF9mYzZydk8xSnRtWkltWE4?oc=5", "source_name": "ACCESS Newswire", "published_at": "2026-05-01T13:03:51+00:00", "published_display": "01 May 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bloomberg TV to air Anixa CEO on cancer vaccine and CAR-T data", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOQktIcW1kSjNKVXd0emUxS1Itcl9sNWNuckFXVjhZNHduQ2Eyall3blBNZm9FS19TdlI4SlltN3drSXV2bzJZWkNpLVpwSnlZUjM2ZjlFWkEwd2dQNGZ3Sm5jNmY4V0VCaDltYkJqRVlHQ2toOVcyMGo0Q1VBTDRpUFFwekdMbTJTM1RVSnFTQjVvejgxUVBsdlhZVW4zQUNYTkw5bjQxMWwtOGhEaWx3S19RcTNIVVBOWTZNdFhmQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIXA BIOSCIENCES ($ANIX) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNRlo3WVJlNWM3bGhuanl1SUIwMExJQ0tCaTNDcXlRbzNTR2VXUEdKYnlZRnMzY3VKN0ZTVG11OWtXRDlvTTRJNnJtUl9HaXVrYzN4UF9yNjJmdDktZnV0bXJrTG13OHhrRUV4UmdnWUJVbHp3QWVmbWVYOGNfTktDbDBjMjh0bGFfWnZGZXNNSGVwUDMt?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1jY2VBeGQ3X0VUU3d1aWRMaTRNQ0NLdERhVTB3Y1RQdFBYakM2U3hQTUFfLXdJV2ZCYnVja2U1TEM2RUpxeHJaNXlhbFdGYU5SYWVrY0ppVFFGVExTYzJFQTlYNG0wbUhjeXV5RnZpNTVyT0pfcUlv?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1rVy1OUG1pbmxHZjMtdDI5V0hkYWFVaE03cVRSZXZaZnZnQTlycUQxTVBJQ3VSSWFuMUhOMzg2S3lOeEMybTR4WEtIcHg3Q1NQMy1VRDJtS1VaQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-09-16T02:53:13+00:00", "published_display": "16 Sep 2020 02:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "CEO Amit Kumar Increases Stake in Anixa Biosciences Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQZ2E3QUtZbl9Lc2RvSlZ0SVQ1Q3NMckp4WkJHZ2ZuTVlkSU5IQ21KRkNqNjJWR1d6VG8xZDBGdW9hNWpxdW1RamtYamJPNE9mOVhQOWZaOTBpcVVNMTZwUFBOVDBraGJuY3J6MjNxNURSN3ZTU216ZzdUMG5PQ294TlJyTWoybWVmT0tmdGJlc29TeVZNZTFfRnR3?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-22T00:30:35+00:00", "published_display": "22 Jul 2026 00:30", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) CEO buys 5,000 common shares", "summary": "Anixa Biosciences Inc.'s CEO and director, Amit Kumar, purchased 5,000 shares of common stock at $3.46 per share on July 20, 2026. This transaction was an open-market or private purchase, increasing his direct holdings to 640,812 shares. The purchase was not made under a Rule 10b", "url": "https://www.stocktitan.net/sec-filings/ANIX/form-4-anixa-biosciences-inc-insider-trading-activity-ce1b9ddfcf24.html", "source_name": "Stock Titan", "published_at": "2026-07-21T14:41:38", "published_display": "21 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Titterton Lewis H Jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX)", "summary": "Titterton Lewis H Jr, a Director at Anixa Biosciences Inc (ANIX), recently purchased 12,000 shares of the company, increasing his total holdings to 986,967 shares. This purchase is part of a trend of insider buying at ANIX, with 8 insider buys and no sells in the past year. Share", "url": "https://www.gurufocus.com/news/8967959/insider-buying-titterton-lewis-h-jr-acquires-additional-shares-of-anixa-biosciences-inc-anix", "source_name": "GuruFocus", "published_at": "2026-07-21T00:40:43", "published_display": "21 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) director purchases 12,000 shares of common stock", "summary": "Anixa Biosciences director Lewis H. Titterton Jr. purchased 12,000 shares of common stock on July 20, 2026, at $3.47 per share. This transaction increases his direct holdings to 986,967 shares and was classified as an open market or private purchase. The Form 4 filing indicates a", "url": "https://www.stocktitan.net/sec-filings/ANIX/form-4-anixa-biosciences-inc-insider-trading-activity-b1f0031c3220.html", "source_name": "Stock Titan", "published_at": "2026-07-20T22:40:43", "published_display": "20 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Friday's Pre-Market Session", "summary": "This article lists 12 health care stocks experiencing significant movement in Friday's pre-market trading session. It provides details on both gainers like Anixa Biosciences and Barinthus Biotherapeutics, and losers such as Regenxbio and Liminatus Pharma, including their stock pe", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60520138/12-health-care-stocks-moving-friday-s-pre-market-session", "source_name": "Benzinga", "published_at": "2026-07-17T12:11:31", "published_display": "17 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences director buys $9,174 in common stock", "summary": "Anixa Biosciences director Lewis H. Titterton Jr. purchased 2,797 shares of common stock for $9,174 on July 15, 2026, increasing his direct holdings to 974,967 shares. Despite the stock's recent gain, InvestingPro suggests the company may be overvalued. Anixa Biosciences is also ", "url": "https://www.investing.com/news/insider-trading-news/anixa-biosciences-director-buys-9174-in-common-stock-93CH-4795886", "source_name": "Investing.com", "published_at": "2026-07-17T02:11:47", "published_display": "17 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi", "summary": "On July 15, 2026, Anixa Biosciences Inc Director Titterton Lewis H Jr purchased 2,797 shares, increasing his total holdings to 974,967 shares. This transaction reflects positive insider sentiment, as he has acquired 15,633 shares over the past year without any sales. The company ", "url": "https://www.gurufocus.com/news/8962658/insider-buying-titterton-lewis-h-jr-increases-stake-in-anixa-biosciences-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-16T15:09:34", "published_display": "16 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences director buys $9,174 in common stock By Investing.com", "summary": "A director at Anixa Biosciences Inc. (NASDAQ: ANIX), Lewis H. Titterton Jr., purchased 2,797 shares of common stock for $9,174. The company has recently made strides in its clinical trials and intellectual property, including a Phase 1 clinical trial for a CAR-T therapy for ovari", "url": "https://ca.investing.com/news/stock-market-news/anixa-biosciences-director-buys-9174-in-common-stock-93CH-4737551", "source_name": "Investing.com Canada", "published_at": "2026-07-16T13:09:58", "published_display": "16 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Anixa Biosciences Inc For: 16 July By Investing.com", "summary": "This article reports on a Form 4 filing for Anixa Biosciences Inc. on July 16, highlighting the basic announcement without providing further details about the filing's content. It also includes various market data and other news headlines related to the financial sector.", "url": "https://ca.investing.com/news/stock-market-news/form-4-anixa-biosciences-inc-for-16-july-93CH-4737574", "source_name": "Investing.com Canada", "published_at": "2026-07-16T13:09:58", "published_display": "16 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stock", "summary": "Anixa Biosciences Inc. director Lewis H. Titterton Jr. purchased 2,797 shares of ANIX common stock on July 15, 2026, at a price of $3.28 per share. This open-market transaction increased his direct holdings to 974,967 shares. The filing was reported on a Form 4, indicating a neut", "url": "https://www.stocktitan.net/sec-filings/ANIX/form-4-anixa-biosciences-inc-insider-trading-activity-4da250bb5d09.html", "source_name": "Stock Titan", "published_at": "2026-07-16T13:09:34", "published_display": "16 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) Secures New Patent for Breast Cancer Va", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxObXRFX0JHZXE0TTAxcEZZdWh3XzZnbmk2VjR4ZUVjblFjdnhocEVKc2R5dW45dFN6TE1fLW5hVVlDd0xzWUdZbC1rcnFkaF9wRDBwbVdrQ2xpRFdzdU1RRVdXaHpnbWctdjh2dU11SVNDc3U0X1pUdm1PQlZiMjMwQkZsT2Q5Xy1BdTBLNnhtSWZSRmlPM3FUNVhNQmZMb19NQzJ4TmREakRaRmJQN1liN3BWMUs3QTJ2b0JsY0oxcUlzeXBDbTZvSEx0LU10azh1clBvUDd0OTRWUjZtSnp5dEM5blJDM1VFZUtXODdR?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T07:33:47+00:00", "published_display": "15 Jul 2026 07:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "No Approved Vaccines Prevent Breast Cancer; Anixa Expands Coverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPdS03UjFHVzVHTjZXb0l5cjQ3bXByeXlSMFNiOGNvOUxOVER3WGpSWlh2dmJST2VTVmhFS25oTm1HcHZGRTd1OUpjcUJWTk5OelVPSGF6aEsyTVExekQ2UEgyUFdTV0pCNlFzV010RWFpc2NoWEd0WGlJMzNIN29jLVBwMVN5YzdqaW1mb2syNkd4NlliUU9mNzRpVjRCbUZBZDFsNTlwb1NhZy00cXBfZmRRSkp2NENQWjBfVA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T12:33:00+00:00", "published_display": "14 Jul 2026 12:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology", "summary": "Anixa Biosciences announced that IP Australia has accepted a patent for its breast cancer vaccine technology, expanding its global intellectual property portfolio. This patent, licensed from Cleveland Clinic, protects their novel approach to breast cancer treatment and prevention", "url": "https://www.prnewswire.com/news-releases/anixa-biosciences-expands-global-patent-portfolio-with-australian-patent-acceptance-for-breast-cancer-vaccine-technology-302824585.html", "source_name": "PR Newswire", "published_at": "2026-07-14T12:32:50", "published_display": "14 Jul 2026 12:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Recent Share Purchase", "summary": "Anixa Biosciences Inc CEO, Amit Kumar, recently purchased 5,000 shares of the company, bringing his total holdings to 635,812 shares. This transaction is part of a larger trend where Kumar has acquired 31,000 shares over the past year without any sales. The acquisition, seen as a", "url": "https://www.gurufocus.com/news/8955589/ceo-amit-kumar-increases-stake-in-anixa-biosciences-inc-with-recent-share-purchase", "source_name": "GuruFocus", "published_at": "2026-07-13T15:10:53", "published_display": "13 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Anixa Biosciences Inc For: 13 July By Investing.com", "summary": "This article reports on a Form 4 filing for Anixa Biosciences Inc. on July 13. It includes the company name and filing date, and highlights that Anixa Biosciences' stock symbol is ANIX and its price performance at the time of publication was +4.25%. The content is brief and prima", "url": "https://uk.investing.com/news/stock-market-news/form-4-anixa-biosciences-inc-for-13-july-93CH-4767943", "source_name": "Investing.com UK", "published_at": "2026-07-13T14:08:00", "published_display": "13 Jul 2026 14:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) CEO Amit Kumar buys 5,000 shares at $3.04", "summary": "Anixa Biosciences (ANIX) CEO Amit Kumar recently purchased 5,000 shares of common stock at $3.04 each, increasing his direct holdings to 635,812 shares. This open-market transaction, reported via a Form 4 SEC filing, represents a net buy of $15,200. The purchase signals confidenc", "url": "https://www.stocktitan.net/sec-filings/ANIX/form-4-anixa-biosciences-inc-insider-trading-activity-fcd882dd84cc.html", "source_name": "Stock Titan", "published_at": "2026-07-13T13:10:54", "published_display": "13 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial", "summary": "Anixa Biosciences has announced the treatment of the first patient in the fifth cohort of its ovarian cancer CAR-T clinical trial. This trial is evaluating the company's CAR T-cell therapy targeting the folate receptor alpha, a protein commonly found on ovarian cancer cells. The ", "url": "https://www.moomoo.com/news/post/72525377/anixa-biosciences-treats-first-patient-in-fifth-cohort-of-ovarian?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T06:10:00", "published_display": "07 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa\u2019s ovarian cancer CAR-T reaches highest dose, no toxicities seen", "summary": "Anixa Biosciences announced that its FSHR-targeted CAR-T/CER-T trial for recurrent ovarian cancer has advanced to its highest dose level (1x10^7 CAR-positive cells/kg) in cohort 5, with the first patient treated. The company confirmed that no dose-limiting toxicities have been ob", "url": "https://www.stocktitan.net/news/ANIX/anixa-biosciences-and-moffitt-cancer-center-advance-ovarian-cancer-t6pib2dyx1qm.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:40:55", "published_display": "06 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa doses first patient in highest cohort of ovarian trial", "summary": "Anixa Biosciences Inc. has treated the first patient in the highest dose cohort of its Phase 1 clinical trial for a CAR-T therapy targeting recurrent ovarian cancer, with no dose-limiting toxicities observed to date. The therapy, liraltagene autoleucel, targets the follicle-stimu", "url": "https://www.investing.com/news/company-news/anixa-doses-first-patient-in-highest-cohort-of-ovarian-trial-93CH-4776595", "source_name": "Investing.com", "published_at": "2026-07-06T13:10:00", "published_display": "06 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10\u2076/kg dose level.", "summary": "Anixa Biosciences reported that its CAR-T cell therapy clinical trial has shown no dose-limiting toxicities up to the 3x10\u2076/kg dose level. This positive safety data is crucial for exploring higher doses and highlights the therapy's potential for patient tolerability. The company ", "url": "https://www.bitget.com/amp/news/detail/12560605492015", "source_name": "Bitget", "published_at": "2026-07-06T13:09:21", "published_display": "06 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date", "summary": "Anixa Biosciences and Moffitt Cancer Center have advanced their ovarian cancer CAR-T clinical trial to its highest dose level yet, 1x10^7 CAR-positive cells/kg, with no dose-limiting toxicities observed to date. Five patients in the study have survived over a year, with one excee", "url": "https://www.prnewswire.com/news-releases/anixa-biosciences-and-moffitt-cancer-center-advance-ovarian-cancer-car-t-clinical-trial-to-highest-dose-level-to-date-302817267.html", "source_name": "PR Newswire", "published_at": "2026-07-06T12:09:21", "published_display": "06 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIX - Anixa Biosciences Inc Revenue Breakdown", "summary": "This article provides a financial breakdown and performance overview for Anixa Biosciences Inc (ANIX). It details various financial metrics such as market capitalization, income, sales, EPS, and insider/institutional ownership. The report also includes performance indicators like", "url": "https://finviz.com/stock?t=ANIX&ta=1&p=m&ty=rv&r=y5", "source_name": "Finviz", "published_at": "2026-07-04T23:09:21", "published_display": "04 Jul 2026 23:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences secures Korean patent for breast cancer vaccine", "summary": "Anixa Biosciences has secured a Korean patent for its breast cancer vaccine technology, which is exclusively licensed from Cleveland Clinic. This patent extends intellectual property protection in South Korea through 2040, addressing the increasing incidence of breast cancer in t", "url": "https://www.biospectrumasia.com/news/26/27942/anixa-biosciences-secures-korean-patent-for-breast-cancer-vaccine.html", "source_name": "BioSpectrum Asia", "published_at": "2026-06-30T21:10:44", "published_display": "30 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Granted Korean Patent for Breast Cancer Vaccine", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/anixa-biosciences-granted-korean-patent-131412869.html", "source_name": "MT Newswires", "published_at": "2026-06-29T13:14:12+00:00", "published_display": "29 Jun 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040", "summary": "Anixa Biosciences has been granted its first Korean patent for its breast cancer vaccine technology, securing exclusive protection in South Korea through 2040. This expands Anixa's global intellectual property portfolio and strengthens its ability to pursue international developm", "url": "https://www.prnewswire.com/news-releases/anixa-biosciences-granted-first-korean-patent-for-its-breast-cancer-vaccine-extending-global-protection-through-2040-302812489.html", "source_name": "PR Newswire", "published_at": "2026-06-29T13:09:50", "published_display": "29 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa gets first Korean patent for breast cancer vaccine", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQRFlxU0MxYXRvdWJvNUlwQ0xTTUk0U2phdmV6TFlBaEZkWlF5cXFUX0tmSWFkWUhJMUxWZkJFTTcxaTZiY1ZMOHBOSFJpZUFza05nU0dyTldhLUZWdmhGbHhtZ0kxUmpub0p3YTJ3Uzl6eVN6LV9JREU5M2REdldjcnlGQVByQVhheWNSS1gtNVRsa3F1bi1qSHV4RFI0ZVIzUEdYUlIySUVBYXRFSjF6WTlXaG1UT29tV09ZcXZ5TQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Secures Patent for Breast Cancer Vaccine in South Korea", "summary": "Anixa has secured a composition-of-matter patent for its breast cancer vaccine in South Korea, valid until 2040, strengthening its global intellectual property. This patent addresses the rising breast cancer incidence in South Korea and supports future commercialization, followin", "url": "https://intellectia.ai/news/stock/anixa-secures-patent-for-breast-cancer-vaccine-in-south-korea", "source_name": "Intellectia AI", "published_at": "2026-06-28T20:09:50", "published_display": "28 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences, Inc. Actuals & Estimates (DUS:CY71)", "summary": "This article provides financial actuals and estimates for Anixa Biosciences, Inc. (CY71) traded on the Dusseldorf Stock Exchange. It details analyst forecasts with a price target range, historical high and low prices, upcoming earnings reports, net income for recent quarters, and", "url": "https://www.tradingview.com/symbols/DUS-CY71/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:57", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Anixa Biosciences, Inc. \u2013 NASDAQ:ANIX", "summary": "This page from TradingView displays financial information for Anixa Biosciences, Inc. (NASDAQ: ANIX), specifically focusing on its forward price-to-sales ratio. It indicates that the market was closed at the time of viewing, with no trades having occurred. The content primarily h", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:39:56", "published_display": "27 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium", "summary": "Anixa Biosciences announced positive data from its completed Phase 1 breast cancer vaccine trial and positive survival observations from its ongoing Phase 1 CAR-T trial for ovarian cancer. The breast cancer vaccine met all primary endpoints, demonstrating safety and immune respon", "url": "https://www.sahmcapital.com/news/content/anixa-biosciences-reports-positive-data-from-completed-breast-cancer-vaccine-phase-1-trial-and-positive-survival-observations-from-ongoing-car-t-phase-1-trial-at-new-york-academy-of-sciences-frontiers-in-cancer-immunotherapy-symposium-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-26T20:09:50", "published_display": "26 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences stock falls despite Phase 1 trial updates By Investing.com", "summary": "Anixa Biosciences Inc. (NASDAQ:ANIX) shares fell 4% despite the company presenting positive Phase 1 clinical trial data for its breast cancer vaccine and ovarian cancer CAR-T therapy. The breast cancer vaccine, developed with Cleveland Clinic, met all major primary endpoints, gen", "url": "https://m.za.investing.com/news/stock-market-news/anixa-biosciences-stock-falls-despite-phase-1-trial-updates-93CH-4346056?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-26T15:11:00", "published_display": "26 Jun 2026 15:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Anixa Biosciences, Inc. \u2013 NASDAQ:ANIX", "summary": "The article focuses on the enterprise value to EBIT forward for Anixa Biosciences, Inc. (NASDAQ: ANIX). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics in relation to its enterprise value and earnings before intere", "url": "https://www.tradingview.com/symbols/NASDAQ-ANIX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:11:00", "published_display": "26 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa breast cancer vaccine met endpoints; CAR-T survival data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQRFRMRFlCRUl6bWpXeEJzWXI2TkRKczNhV0kwRHRvZklhU3BkVWF6UzZoMnZsVEZ0aUZ3SWdRczRQdS1KejhhS0ZVaW9rOWt3VUFLclBFVkEyZVVXakEwRTM0dU9Mc1oxd1ZLLVY5SFpqUThQTVp3SGliQTllSXZ1bldLLXJBalBtcWNsR3dEZGJOWWhueE9CR2MyeW5nS1JsLU8zVnpqRkhxaXJkWWZmSWx4RTdLbWhBWXRDT0hxSGU?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) director adds 2,836 shares in open-market buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOQ05SLXBmTUtKYXN1LUExc2ZhWjVOdHRsR0xCNG1ibWtNbVdmUkVkemN5NHN1NUpwRXFKZ3QtbHpmV25WTDN1aEYwWnQ1WGVValBDWFB6X0g2bGc2UndFV1RveXRZaEI3aUwtSjF2VHlpS0VMZVFXZ21LNlBKTU5uVnk1MGstNDBvQThBWXMzMm5UVXB0bUphMURQQnY2OUx5Yzhac1ZzV0tObllpTmxSOFRXbnp5Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (NASDAQ: ANIX) CEO adds 21,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOQW1qMThnS2NKc0Y2RGdjVk5SdE1xdm9sX0RpWXpkVWpNcUFFM2xVX2ZRZWdpa3dtYXJwaFljREVxTm1yTlhNYlRMcFpTTHJTdFJiS1JSOWVULVRuZFlLaFNNSElOTGxfSmozeDc1Zmo3R1FETUhPb2hOZnVjZWlqMFltdEdJTzVoWGFHM3lfWUx6NHk0OF9zTWt2REVTLTh2Um43MUxLLTV0ZnU4ZXkxWkw0TXdiUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anixa-biosciences-announces-presentations-two-130500822.html", "source_name": "PR Newswire", "published_at": "2026-06-11T13:05:00+00:00", "published_display": "11 Jun 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Says Canadian IP Office Issues Notice of Allowance for Patent Covering Ovarian Cancer Vaccine Technology", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anixa-biosciences-says-canadian-ip-134434799.html", "source_name": "MT Newswires", "published_at": "2026-06-01T13:44:34+00:00", "published_display": "01 Jun 2026 13:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anixa-biosciences-strengthens-international-patent-130000346.html", "source_name": "PR Newswire", "published_at": "2026-06-01T13:00:00+00:00", "published_display": "01 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "/C O R R E C T I O N -- Anixa Biosciences, Inc./", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/anixa-biosciences-reports-updated-positive-125500267.html", "source_name": "PR Newswire", "published_at": "2026-05-11T15:48:00+00:00", "published_display": "11 May 2026 15:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOajNIYk1TSlBsM0tGMm54V2twWFYwR3JhaVYxTTlBUlYwd1dPUllJVmROU01TVEdTRU5pNVFMWFFrMHpDb3VNNF8xbEp0WUpCLXBWdFN6TVc4UU9QUWJSOGpIWUR5RWkxdVVXem9qdldndFN3QmtpNEJFUG1GV2Qtd3R4VkxnOWNsZ3dtelJRR0oxaW1ORHg0TkN0dll1elJKMnhQLUdJeGN1Z1hrdjNqMDV4ZVdoUjdBWUpFU1ROekQ0VUhIektVSXlDbTQ1ajlpWFBkUF9mYzZydk8xSnRtWkltWE4?oc=5", "source_name": "ACCESS Newswire", "published_at": "2026-05-01T13:03:51+00:00", "published_display": "01 May 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bloomberg TV to air Anixa CEO on cancer vaccine and CAR-T data", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOQktIcW1kSjNKVXd0emUxS1Itcl9sNWNuckFXVjhZNHduQ2Eyall3blBNZm9FS19TdlI4SlltN3drSXV2bzJZWkNpLVpwSnlZUjM2ZjlFWkEwd2dQNGZ3Sm5jNmY4V0VCaDltYkJqRVlHQ2toOVcyMGo0Q1VBTDRpUFFwekdMbTJTM1RVSnFTQjVvejgxUVBsdlhZVW4zQUNYTkw5bjQxMWwtOGhEaWx3S19RcTNIVVBOWTZNdFhmQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ANIXA BIOSCIENCES ($ANIX) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNRlo3WVJlNWM3bGhuanl1SUIwMExJQ0tCaTNDcXlRbzNTR2VXUEdKYnlZRnMzY3VKN0ZTVG11OWtXRDlvTTRJNnJtUl9HaXVrYzN4UF9yNjJmdDktZnV0bXJrTG13OHhrRUV4UmdnWUJVbHp3QWVmbWVYOGNfTktDbDBjMjh0bGFfWnZGZXNNSGVwUDMt?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1jY2VBeGQ3X0VUU3d1aWRMaTRNQ0NLdERhVTB3Y1RQdFBYakM2U3hQTUFfLXdJV2ZCYnVja2U1TEM2RUpxeHJaNXlhbFdGYU5SYWVrY0ppVFFGVExTYzJFQTlYNG0wbUhjeXV5RnZpNTVyT0pfcUlv?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anixa Biosciences (ANIX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1rVy1OUG1pbmxHZjMtdDI5V0hkYWFVaE03cVRSZXZaZnZnQTlycUQxTVBJQ3VSSWFuMUhOMzg2S3lOeEMybTR4WEtIcHg3Q1NQMy1VRDJtS1VaQQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-09-16T02:53:13+00:00", "published_display": "16 Sep 2020 02:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 54, "sentiment_summary": {"positive": 23, "negative": 4, "neutral": 27, "score": 60, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 19.8, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 3.4, "latest_week": "2026-07-17", "one_week_move": 11.1, "four_week_move": 16.8, "twelve_week_move": 11.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.238418, "market_dynamics_buy_signal": false, "relative_strength": -5.636546, "fair_value_gap": 6.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 45.0608, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+11.1% over one week, +16.8% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 71, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 7}, {"label": "PR Newswire", "count": 6}, {"label": "GuruFocus", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "Investing.com Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+11.1% over one week, +16.8% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "CEO Amit Kumar Increases Stake in Anixa Biosciences Inc"}], "updated_at": "2026-07-22T03:51:32.601289+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}